Ceftazidime-Avibactam Market Size to Hit USD 7.15 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Ceftazidime-Avibactam Market

5.1. COVID-19 Landscape: Ceftazidime-Avibactam Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Ceftazidime-Avibactam Market, By Formulation

8.1. Ceftazidime-Avibactam Market Revenue and Volume Forecast, by Formulation

8.1.1. Intravenous (IV) Injection

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Lyophilized Powder

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Ceftazidime-Avibactam Market, By Indication

9.1. Ceftazidime-Avibactam Market Revenue and Volume Forecast, by Indication

9.1.1. Complicated Urinary Tract Infections (cUTIs)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Complicated Intra-Abdominal Infections (cIAIs)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Bloodstream Infections (BSIs)

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Bloodstream Infections (BSIs)

9.1.5.1. Market Revenue and Volume Forecast

Chapter 10. Global Ceftazidime-Avibactam Market, By End User

10.1. Ceftazidime-Avibactam Market Revenue and Volume Forecast, by End User

10.1.1. Hospitals

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Clinics

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Ambulatory Care Centers

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Ceftazidime-Avibactam Market, By Distribution Channel

11.1. Ceftazidime-Avibactam Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Hospital Pharmacy

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail Pharmacy

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online Pharmacy

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Ceftazidime-Avibactam Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Formulation

12.1.2. Market Revenue and Volume Forecast, by Indication

12.1.3. Market Revenue and Volume Forecast, by End User

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Formulation

12.1.5.2. Market Revenue and Volume Forecast, by Indication

12.1.5.3. Market Revenue and Volume Forecast, by End User

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Formulation

12.1.6.2. Market Revenue and Volume Forecast, by Indication

12.1.6.3. Market Revenue and Volume Forecast, by End User

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Formulation

12.2.2. Market Revenue and Volume Forecast, by Indication

12.2.3. Market Revenue and Volume Forecast, by End User

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Formulation

12.2.5.2. Market Revenue and Volume Forecast, by Indication

12.2.5.3. Market Revenue and Volume Forecast, by End User

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Formulation

12.2.6.2. Market Revenue and Volume Forecast, by Indication

12.2.6.3. Market Revenue and Volume Forecast, by End User

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Formulation

12.2.7.2. Market Revenue and Volume Forecast, by Indication

12.2.7.3. Market Revenue and Volume Forecast, by End User

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Formulation

12.2.8.2. Market Revenue and Volume Forecast, by Indication

12.2.8.3. Market Revenue and Volume Forecast, by End User

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Formulation

12.3.2. Market Revenue and Volume Forecast, by Indication

12.3.3. Market Revenue and Volume Forecast, by End User

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Formulation

12.3.5.2. Market Revenue and Volume Forecast, by Indication

12.3.5.3. Market Revenue and Volume Forecast, by End User

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Formulation

12.3.6.2. Market Revenue and Volume Forecast, by Indication

12.3.6.3. Market Revenue and Volume Forecast, by End User

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Formulation

12.3.7.2. Market Revenue and Volume Forecast, by Indication

12.3.7.3. Market Revenue and Volume Forecast, by End User

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Formulation

12.3.8.2. Market Revenue and Volume Forecast, by Indication

12.3.8.3. Market Revenue and Volume Forecast, by End User

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Formulation

12.4.2. Market Revenue and Volume Forecast, by Indication

12.4.3. Market Revenue and Volume Forecast, by End User

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Formulation

12.4.5.2. Market Revenue and Volume Forecast, by Indication

12.4.5.3. Market Revenue and Volume Forecast, by End User

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Formulation

12.4.6.2. Market Revenue and Volume Forecast, by Indication

12.4.6.3. Market Revenue and Volume Forecast, by End User

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Formulation

12.4.7.2. Market Revenue and Volume Forecast, by Indication

12.4.7.3. Market Revenue and Volume Forecast, by End User

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Formulation

12.4.8.2. Market Revenue and Volume Forecast, by Indication

12.4.8.3. Market Revenue and Volume Forecast, by End User

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Formulation

12.5.2. Market Revenue and Volume Forecast, by Indication

12.5.3. Market Revenue and Volume Forecast, by End User

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Formulation

12.5.5.2. Market Revenue and Volume Forecast, by Indication

12.5.5.3. Market Revenue and Volume Forecast, by End User

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Formulation

12.5.6.2. Market Revenue and Volume Forecast, by Indication

12.5.6.3. Market Revenue and Volume Forecast, by End User

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Sun Pharmaceutical Industries Ltd.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Dr. Reddy’s Laboratories

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Amneal Pharmaceuticals

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Hetero Drugs Ltd.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Glenmark Pharmaceuticals

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Natco Pharma Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Jubilant Life Sciences, and

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Alembic Pharmaceutical

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Allergan plc

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Pfizer Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The ceftazidime-avibactam market size is expected to increase from USD 3.3 billion in 2024 to USD 7.15 billion by 2034.

The ceftazidime-avibactam market is expected to grow at a compound annual growth rate (CAGR) of around 8.05% from 2025 to 2034.

The major players in the ceftazidime-avibactam market include Pfizer Inc., Allergan plc, Cipla Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Sandoz International GmbH, Hikma Pharmaceuticals, Aurobindo Pharma Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Mylan N.V., Zydus Cadila, Torrent Pharmaceuticals Ltd., Amneal Pharmaceuticals, Hetero Drugs Ltd., Glenmark Pharmaceuticals, Natco Pharma Ltd., Jubilant Life Sciences, and Alembic Pharmaceuticals

The driving factors of the ceftazidime-avibactam market are due to the rising incidence of multidrug-resistant gram-negative infections, which is driving its demand in clinical settings

North America region will lead the global ceftazidime-avibactam market during the forecast period 2025 to 2034.